Dr. Kitchens: Predicting IOP Response


OUR COLLEAGUE: John W. Kitchens, MD — Lexington, KY

"If the patient is not responding sufficiently to your current therapy, you owe it to them to treat the edema and trust either yourself or your colleagues to manage the rest, if needed."
— John W. Kitchens, MD

Above results are from a single case; results may vary.


Dr. Kitchens is a partner and practicing retinal specialist at Retina Associates of Kentucky, the largest “retina only” practice in the state. He has been voted one of the “Best Doctors in America” and one of “America’s Top Ophthalmologists.”

Academic affiliations:
  • Received his MD from the Indiana University School of Medicine
  • Completed his ophthalmology residency at the University of Iowa Hospitals and Clinics Eye and Ear Infirmary followed by a vitreoretinal fellowship at the University of Chicago Department of Ophthalmology and Visual Sciences
  • Was Chief Resident at Bascom Palmer Eye Institute in Miami, Florida where he also completed his retinal fellowship


Patient Profile 1
Sex: Male
Age: 64
Diagnosis: DME
Treated Eye: OD
Lens Status: Pseudophakic
Concomitant conditions:
  • Poorly controlled Type II diabetes mellitus
Treatment history:
30X anti-VEGF therapy (bevacizumab, ranibizumab and a ibercept)
11X corticosteroid (intravitreal triamcinolone and dexamethasone)
1X grid laser

Reasons Dr. Kitchens chose ILUVIEN:
  • This patient experienced a gradual waning of response to anti-VEGF therapy
  • Patient concern with frequent injections
  • Prior IOP elevation with corticosteroid therapy was managed effectively with topical drops and considered not clinically significant


Retinal Thickness (µm)
Retinal Thickness
Best Corrected Visual Acuity (BCVA)
Best Corrected Visual Acuity
IOP: Intraocular Pressure
Intraocular Pressure


Patient Results
ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg:

Patient Outcome
  • ILUVIEN treatment with CONTINUOUS MICRODOSING™ Delivery was initiated with the goal of providing a long-lasting treatment
  • In this patient, ILUVIEN has provided sustained results for 14 months with just one additional anti-VEGF injection
  • Improvement was seen in both visual acuity and retinal edema
  • With ongoing topical therapy, no clinically significant rise in IOP has been observed
Selected OCT Scans
References:
1. Data on File. Alimera Sciences, Inc.



"For this patient, I decided that ILUVIEN was the best course of therapy, despite his history of an IOP response. I pretreated him with drops and things seem to be going really well."
— Dr. Kitchens